FCS Press Releases

Cancer experts continue to expand the number and scope of clinical trial opportunities available to cancer patients. More than 200 patients in Lee County participate in early phase clinical studies each year. 

FCS published a case study showcasing the practice’s multi-year track record of delivering savings as a participant in the Oncology Care Model.

FCS entered a five-year demonstration project aimed at improving the overall quality of cancer care and reducing the trend of cancer care costs.

Florida Cancer Specialists & Research Institute (FCS) announces that Tonja A. Wise, MHA, CHC, CHPC, CCS has joined its senior management team as Vice President of Compliance.

Michael Diaz, MD and Faithlore Gardner, MD from Florida Cancer Specialists & Research Institute (FCS) participated in the Florida Society of Clinical Oncology (FLASCO) Fellow & Resident Educational Training Program held March 19, 2022 in Orlando, Florida.

Florida Cancer Specialists & Research Institute (FCS) launched a new website, Florida Cancer Specialists Hematology Oncology Review (FCSHemOncReview.com), to host a variety of top articles ranging from recent oncology and hematology studies to new therapies, even topics on value-based care.

Physicians and senior leaders of Florida Cancer Specialists & Research Institute (FCS) will be participating in the 2022 Community Oncology Conference hosted by the Community Oncology Alliance (COA) this week in Kissimmee, Florida.

Florida Cancer Specialists & Research Institute (FCS) is pleased to welcome Ken Sturtz, MBA, MHA to its executive leadership team as Chief Information Officer. He will oversee all information technology operations and drive digital innovation company-wide.

Three Florida Cancer Specialists & Research Institute (FCS) physicians presented clinical research findings at the American Society of Clinical Oncology (ASCO®) 2022 Genitourinary Cancers Symposium held February 17 – 19 in San Francisco, CA.

Medical oncologists Lucio  N. Gordan, MD and Ivor Percent, MD, members of the clinical research team at Florida Cancer Specialists & Research Institute (FCS), are co-authors for a study that examined the safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC) administered primarily in community-based settings.

Lime Connect (Lime) is pleased to announce that Nathan H. Walcker, Chief Executive Officer of Florida Cancer Specialists & Research Institute, has joined the not for profit organization as a member of its global board of directors.

Dr. Phelan identified the chromosome variant now known as Phelan-McDermid Syndrome

FCS announced the newest addition to its senior management team. Joshua Eaves joined FCS as Senior Vice President Corporate Development.

Hodgkin lymphoma, named after Dr. Thomas Hodgkin, is a cancer that affects the lymphatic system which makes up part of the body’s immune system. Specifically, Hodgkin lymphoma occurs when the DNA changes in white blood cells called lymphocytes.

Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologists Ivor Percent, MD, Maen Hussein, MD, and Viralkumar Bhanderi, MD, contribute observations for Phase II study. Another presentation at ASCO GI 2022 includes Phase I observations from FCS physician, Manish R. Patel, MD.

The sports world is mourning the loss of Jim Corsi who passed away after a battle with liver and colon cancer.